News Tag: 2021 newsletters

Assessing the Maximum-Tolerated Dose of AMG 232 (KRT-232) with Concurrent Radiotherapy in the Treatment of Soft Tissue Sarcoma with Wild-Type P53 Gene (NRG-DT001)

Read More

Congratulations to the NRG Oncology Members Assigned to NCI Gastrointestinal Task Forces

Read More

Getting Started with Radiation Therapy (RT) Credentialing (September 2021 Newsletter)

Read More

NRG-CC005 (FORTE): Five- or Ten-Year Colonoscopy for 1-2 Non-Advanced Adenomatous Polyps (September 2021 Newsletter)

Read More

NRG Oncology Health Equity New Investigator Mentor Program for Underrepresented Minority (URM) Scholars (September 2021 Newsletter)

Read More

OvCa Survivors and Thrivers Make Remarkable Strides in Research (Sept 2021 Newsletter)

Read More

Highlighting NRG Gynecologic Studies: Gynecologic Cancer Awareness Month (Sept 2021 Newsletter)

Read More

NRG Oncology Limited-Stage Small Cell Lung Cancer Trial Participant Interviewed on his Journey

Read More

Opinion: Adoption of Clinical Research Competencies can Set the Stage for Research Success

Read More

Assessing the Maximum-Tolerated Dose and the Efficacy of Tocilizumab and Atezolizumab in the Treatment of Recurrent Glioblastoma (NRG-BN010)

Read More